About us

We are united behind a new approach to personalized immunotherapy

Our expert leadership team draws on many decades of experience in complementary areas of biopharma development and commercialization, which they bring to bear on Imvax’s strategy to deliver a portfolio of therapies targeting solid tumors.

Meet our leadership team


John P. Furey

Chief Executive Officer

david andrews

David W. Andrews, M.D.

Co-Founder, Chief Medical Officer

mark exley

Mark A. Exley, Ph.D.

Chief Scientific Officer

sean hemingway

Sean P. Hemingway

Chief Operating Officer

john limongelli

John M. Limongelli

Chief Legal Officer


Diana Martine

Head of Human Resources

josh muntner

Josh Muntner

Chief Financial Officer

steven altschuler

Steven M. Altschuler, M.D.

Ziff Capital Partners

iran brind

Ira Brind

President, Brind Investments, Inc.

david bunning

David G. Bunning

TLP Investment Partners LLC

peter corr

Peter B. Corr, Ph.D.

Co-Founder, Chairman of the Board

wendy dicicco

Wendy DiCicco

Board Advantage, LLC


John P. Furey

Chief Executive Officer


Ted Koutouzis, M.D.

Quantitative Bio

thomas pfisterer

Thomas Pfisterer

Wild Group Management AG

Stephen Webster

Stephen Webster

Former CFO, Spark Therapeutics

shefali agarwal

Shefali Agarwal, M.D.


tyler curiel

Tyler Curiel, M.D.

Dartmouth College

Corporate Presentation

View our corporate presentation at the link below

Corporate Infographic

View our corporate infographic at the link below